drugset / Trial / NCT04914598
A Phase Ⅲ Clinical Study of Combined Cisplatin Versus Placebo Combined With Intracavitary Cisplatin Injection in the Treatment of Malignant Pleural Effusions
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Malignant Pleural Effusion or Ascites is a common complication of malignant tumor, The objective of this study is to compare the efficacy of Endostar/cisplatin with placebo/cisplatin in patients with malignant pleural effusion or ascites.
Timeline
- Start
- 2021-07-28
- Primary completion
- 2025-02-10
- Completion
- 2026-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Endostar | Protein / enzyme biologic | 45 mg | Other |
| Comparator | Endostar | Protein / enzyme biologic | 60 mg | Other |
| Comparator | Cisplatin | Other / unclassified | 40 mg | Other |